Emcure Pharmaceuticals

1,284.40
+116.70
(9.99%)
Market Cap
22,120.00 Cr
EPS
27.54
PE Ratio
32.24
Dividend Yield
0.26 %
Industry
Healthcare
52 Week High
1,580.00
52 Week Low
889.00
PB Ratio
4.99
Debt to Equity
0.86
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+66.67 %
+66.67 %
Hold
Hold+33.33 %
+33.33 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
positive
Emcure Pharmaceuticals: Q4 Profit Surges 64%, Announces DividendToday
Emcure Pharmaceuticals reported a 64% increase in Q4 net profit to Rs 189 crore. Revenue rose to Rs 2,116 crore, with margins expanding to 19%. The company announced a dividend of Rs 3 per share and plans to incorporate a wholly-owned subsidiary, Emcure Generics Pvt.
positive
Emcure Pharmaceuticals: Kotak Raises Price Target by 39% Post Q4 ResultsToday
Kotak Institutional Equities increased its price target for Emcure Pharma to ₹1,625 from ₹1,515, maintaining a 'buy' rating. Emcure's Q4 results showed 19.5% YoY revenue growth and 29.5% YoY EBITDA increase. The stock hit a 10% upper circuit at ₹1,284.4, up 27% from its IPO price.
positive
Emcure Pharmaceuticals: Q4 Profit Surges 64%, Stock Rises 8%1 day ago
Emcure Pharmaceuticals reported a 64% year-on-year increase in Q4 net profit to ₹189 crore. Revenue grew 20% to ₹2,116 crore. The board recommended a final dividend of ₹3 per share. Stock price rose 8% following the announcement.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,683.60
#1 4,12,373.70
34.99
#1 49,887.20
12.06
#1 9,648
-18.99
40.74
6,483.00
1,73,563.40
79.22
8,184.00
0.89
1,600
23.05
63.44
1,484.20
1,18,598.30
22.48
26,520.70
14.17
4,155
30.28
47.86
3,174.70
1,08,708.70
56.40
10,785.70
11.59
1,656
10.91
43.82
1,230.10
1,01,987.10
#1 18.04
28,905.40
12.36
5,578
21.14
62.40
2,432.40
1,00,636.20
50.63
10,615.60
19.57
1,942
-10.91
44.37
908.60
90,908.20
19.48
19,831.50
13.82
3,831
-0.19
56.78
1,978.90
89,879.20
27.39
20,141.50
#1 19.94
1,936
#1 112.49
44.10
1,197.10
69,010.80
19.58
29,559.20
17.55
3,169
-10.04
50.83
30,795.00
66,181.00
46.72
6,097.20
10.80
1,201
27.83
54.40
Forecast
Actual
Growth Rate
Revenue Growth
11.33 %
Net Income Growth
-6.09 %
Cash Flow Change
46.92 %
ROE
-20.28 %
ROCE
-20.23 %
EBITDA Margin (Avg.)
-5.80 %

Quarterly Financial Results

Quarterly Financials
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Revenue
1,571
1,664
1,697
1,783
1,839
2,038
1,959
2,121
Expenses
1,261
1,337
1,381
1,460
1,479
1,621
1,601
1,724
EBITDA
311
327
316
323
360
417
359
397
Operating Profit %
19 %
20 %
17 %
18 %
19 %
19 %
18 %
19 %
Depreciation
67
70
84
91
94
97
97
97
Interest
52
59
61
66
59
46
32
39
Profit Before Tax
191
198
171
167
207
273
230
261
Tax
50
52
51
46
55
72
74
63
Net Profit
141
146
120
121
153
202
156
197
EPS in ₹
7.21
7.70
6.27
6.36
7.95
10.23
8.12
9.97

Balance Sheet

Balance Sheet
2018
2019
2020
2021
2022
2023
2024
Total Assets
5,247
5,644
6,004
6,807
6,064
6,673
7,806
Fixed Assets
2,049
2,247
2,382
2,188
2,044
2,147
3,125
Current Assets
2,335
2,453
2,703
3,718
3,424
3,836
4,260
Capital Work in Progress
531
581
485
302
320
411
159
Investments
0
0
0
0
25
25
318
Other Assets
2,667
2,817
3,137
4,318
3,674
4,089
4,204
Total Liabilities
5,247
5,644
6,004
6,807
6,064
6,673
7,806
Current Liabilities
2,336
2,543
2,920
3,408
2,965
3,019
3,211
Non Current Liabilities
1,157
1,201
1,100
1,031
985
1,004
1,474
Total Equity
1,755
1,900
1,984
2,368
2,114
2,650
3,122
Reserve & Surplus
1,520
1,654
1,731
2,092
1,807
2,320
2,771
Share Capital
181
181
181
181
181
181
181

Cash Flow

Cash Flow
2019
2020
2021
2022
2023
2024
Net Cash Flow
-700
32
259
42
134
219
Investing Activities
-409
-168
-257
-575
-468
-715
Operating Activities
444
500
704
768
747
1,097
Financing Activities
-735
-301
-189
-152
-145
-164

Share Holding

% Holding
Jul 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
78.08 %
78.08 %
77.94 %
77.92 %
FIIs
1.76 %
2.91 %
3.05 %
3.07 %
DIIs
3.34 %
3.96 %
3.87 %
3.44 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.73 %
5.00 %
5.14 %
5.51 %
Others
9.10 %
10.04 %
10.00 %
10.06 %
No of Share Holders
4,98,006
1,52,914
1,43,449
1,39,671

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
22 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
22 May 2025 1,036.35 1,073.60
06 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Feb 2025 1,345.75 1,249.80
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Nov 2024 1,406.40 1,444.25

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication2 hours ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome1 day ago
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 20151 day ago
Announcement under Regulation 30 (LODR)-Acquisition1 day ago
Appointment Of Secretarial Auditor1 day ago
Announcement under Regulation 30 (LODR)-Change in Management1 day ago
Audited Financial Results For The Quarter And Year Ended March 31 20251 day ago
Corporate Action-Board approves Dividend1 day ago
Board Meeting Outcome for Outcome Of Board Meeting Held On May 22 20251 day ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation9 days ago
Board Meeting Intimation for Approval Of Audited Financial Results (Standalone And Consolidated) For The Quarter And Year Ended March 31 20259 days ago
Announcement Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - Update On USFDA Inspection At API Manufacturing Facility Located At Kurkumbh Pune Maharashtra IndiaApr 18, 2025
Intimation Of Change In Email And Website Address Of Registrar And Share Transfer Agent Of The CompanyApr 18, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 08, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 01, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 31, 2025
Closure of Trading WindowMar 25, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 10, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - US FDA Inspection At API Manufacturing Facility Located At KuFeb 26, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) - US FDA Inspection At API Manufacturing Facility Located At Kurkumbh Pune Maharashtra IndiaFeb 26, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 11, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderFeb 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 06, 2025
Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations 2015Feb 06, 2025
Integrated Filing (Financial)Feb 06, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On February 06 2025Feb 06, 2025
Unaudited Financial Results (Consolidated And Standalone) For The Quarter And Nine Months Ended December 31 2024Feb 06, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderFeb 05, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderFeb 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 24, 2025
Board Meeting Intimation for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31 2024Jan 24, 2025
Press Release Titled Emcure Pharmaceuticals Inaugurates World-Class R&D Centre In Gujarat.Jan 23, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2025
Intimation Of Change In Name Of Registrar And Share Transfer Agent Of The CompanyJan 02, 2025
Closure of Trading WindowDec 18, 2024
Announcement under Regulation 30 (LODR)-Change in ManagementNov 29, 2024
Announcement under Regulation 30 (LODR)-Resignation of DirectorNov 23, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 23, 2024
Shareholder Meeting / Postal Ballot-Notice of Postal BallotNov 22, 2024
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSNov 22, 2024
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 13, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 08, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2024
Statement Of Deviation(S) Or Variation(S) Of Funds Under Regulation 32 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, For The Quarter Ended September 30, 2024Nov 07, 2024
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 07, 2024
Board Meeting Outcome for Outcome Of Board Meeting Held On November 07, 2024Nov 07, 2024
Results - Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 07, 2024

Technical Indicators

RSI(14)
Neutral
70.37
ATR(14)
Volatile
51.49
STOCH(9,6)
Neutral
77.64
STOCH RSI(14)
Overbought
96.27
MACD(12,26)
Bullish
12.98
ADX(14)
Weak Trend
19.92
UO(9)
Bearish
50.03
ROC(12)
Uptrend And Accelerating
14.92
WillR(14)
Neutral
-38.72

About Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited is an Indian pharmaceutical company founded in 1981. It develops, manufactures, and globally markets pharmaceutical products across various therapeutic areas. The company operates 13 manufacturing facilities in India and has a presence in over 70 countries, with a strong focus on India, Europe, and Canada. Emcure specializes in orals, injectables, and biotherapeutics, covering areas such as gynecology, cardiovascular, vitamins, minerals, nutrients, HIV antivirals, blood-related, and oncology treatments. The company has a portfolio of differentiated products, including chiral molecules, complex APIs, biologics, and novel drug delivery systems. Emcure has commercialized six in-house manufactured biologics and holds patents for specific treatments. The company expanded through mergers, acquisitions, and establishment of new facilities over the years. In July 2024, Emcure launched an Initial Public Offer.
Listing Date
10 Jul, 2024(0 Years, 43 days)
Chairperson NameBerjis M Desai